Combination use of insulin and incretins in type 2 diabetes
The objective of this review was to summarize and critically appraise the evidence regarding the clinical effectiveness and harms of combination use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogues with insulin. The following research questions were assessed:...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
[2013], 2013
|
| Series: | CADTH optimal use report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this review was to summarize and critically appraise the evidence regarding the clinical effectiveness and harms of combination use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogues with insulin. The following research questions were assessed: 1. What is the clinical efficacy and safety of DPP-4 inhibitors used in combination with insulin for patients with inadequate glycemic control on a basal or biphasic insulin regimen? 2. What is the clinical efficacy and safety of GLP-1 analogues used in combination with insulin for patients with inadequate glycemic control on a basal or biphasic insulin regimen? |
|---|---|
| Item Description: | "July 2013." |
| Physical Description: | 1 PDF file (ii, 18 pages) illustrations |